Article info

Download PDFPDF

Original article
Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients

Authors

  • Sergio Prieto-González Department of Autoimmune Diseases, Vasculitis Research Unit, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CRB-CELLEX, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Nekane Terrades-García Department of Autoimmune Diseases, Vasculitis Research Unit, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CRB-CELLEX, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Marc Corbera-Bellalta Department of Autoimmune Diseases, Vasculitis Research Unit, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CRB-CELLEX, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Ester Planas-Rigol Department of Autoimmune Diseases, Vasculitis Research Unit, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CRB-CELLEX, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Chie Miyabe Division of Rheumatology, Allergy and Immunology, Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Marco A Alba Department of Autoimmune Diseases, Vasculitis Research Unit, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CRB-CELLEX, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Ariel Ponce Department of Autoimmune Diseases, Vasculitis Research Unit, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CRB-CELLEX, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Itziar Tavera-Bahillo Department of Autoimmune Diseases, Vasculitis Research Unit, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CRB-CELLEX, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Giuseppe Murgia Department of Autoimmune Diseases, Vasculitis Research Unit, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CRB-CELLEX, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Georgina Espígol-Frigolé Department of Autoimmune Diseases, Vasculitis Research Unit, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CRB-CELLEX, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Javier Marco-Hernández Department of Autoimmune Diseases, Vasculitis Research Unit, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CRB-CELLEX, Barcelona, Spain PubMed articlesGoogle scholar articles
  • José Hernández-Rodríguez Department of Autoimmune Diseases, Vasculitis Research Unit, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CRB-CELLEX, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Ana García-Martínez Department of Emergency Medicine, Hospital Clínic, University of Barcelona, IDIBAPS, CRB-CELLEX, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Sebastian H Unizony Division of Rheumatology, Allergy and Immunology, Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Maria C Cid Department of Autoimmune Diseases, Vasculitis Research Unit, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CRB-CELLEX, Barcelona, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Sergio Prieto-González; sprieto{at}clinic.ub.es and Dr Maria C Cid; mccid{at}clinic.ub.es
View Full Text

Citation

Prieto-González S, Terrades-García N, Corbera-Bellalta M, et al
Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients

Publication history

  • Received September 4, 2017
  • Revision received October 23, 2017
  • Accepted November 24, 2017
  • First published December 22, 2017.
Online issue publication 
December 22, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.